MedTrace Logo

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

NCT00446654 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2012-08-06

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to determine how safe and effective subconjunctival injections of CGC-11047 are in subjects with wet age related macular degeneration at two different dosing intervals.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

CGC-11047

16.5 mg (3.3%) subconjunctival injection

Sponsors & Collaborators

  • Progen Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Peter Campochiaro, MD · Wilmer Eye Institute, Johns Hopkins Hospital School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States
  • Mexico
  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00446654 on ClinicalTrials.gov